Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?-Reference-Cited by-同舟云学术

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

Published:2009-02 Issue:2 Volume:84 Page:161-169
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Jabbour Elias,Cortes Jorge E.,Kantarjian Hagop M.

Publisher

Elsevier BV

Subject

General Medicine

Reference92 articles.

1. Chronic myeloid leukaemia;Hehlmann;Lancet,2007

2. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase;Johnson;Clin Cancer Res,2003

3. Gleevec (imatinib mesylate)[package insert],2007

4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

5. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia;Kantarjian;Blood,2006

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia;Cureus;2024-03-20

2. Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study;International Journal of Molecular Sciences;2023-06-14

3. Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defense;Frontiers in Immunology;2022-09-29

4. Targeting tumor stemness switch phenotype by activating pathogen induced stem cell niche defense;2022-03-27

5. Treatment Responses in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors (TKI) Therapy;Pakistan Journal of Medical and Health Sciences;2021-09-30